Structure Therapeutics
Market cap $3.90B 214.8M shares (10-Q, Oct 31, 2026) × $18.17 close Nov 17, 2026
Most recent annual filing: 2026-02-26
- aleniglipron Ph2 topline4Q 2026aleniglipron Ph2 topline, 4Q 2026, major
- ACCG-3535 / combination trial Ph14Q 2026ACCG-3535 / combination trial Ph1, 4Q 2026, notable
- WuXi AppTec / BIOSECURE corporateDec 2026WuXi AppTec / BIOSECURE corporate, Dec 2026, routine
- ACCG-2671 Ph1 readout1H 2027ACCG-2671 Ph1 readout, 1H 2027, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (5 active programs)
ACCG-2671
ACCG-3535
LTSE-2578
Technology platforms
Structure-Based Drug Discovery Platform · Schrödinger
GPCR-focused structure-based drug discovery platform combining 3D protein structure visualization, computational chemistry, and physics-based methods in collaboration with Schrödinger. Targets GPCRs in metabolic, cardiovascular, and pulmonary diseases, enabling design of oral small molecule therapeutics against targets historically limited to peptides or biologics.
Targets: GPCRs
GPCR Structure-Based Drug Discovery
Structure-based drug discovery and computational chemistry platform focused on G-protein coupled receptors (GPCRs); targets metabolic, cardiovascular, pulmonary and neurological disorders including obesity, T2DM, MASH, heart failure, sleep apnea, chronic kidney disease, and osteoarthritis.
Targets: GIPR, GCGR, GLP-1R
Discontinued (1)
- ANPA-0073 — undisclosed · decided not suitable for selective weight loss; deprioritized in favor of other discovery stage APJ receptor agonists
Capital (as filed)
- Cash
- $222M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $1.02B Sep 30, 2026
- Operating cash flow
- −$102M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $1.24B cash, runway through the end of 2028 per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (5)
- 2026-11-10 UPDATE: Structure Therapeutics (GPCR) - Half the Price, Same Molecule 🔒 Paid
- 2026-09-09 UPDATE: Structure Therapeutics (GPCR) - The Amylin Data Landed, and So Did the Stock 🔒 Paid
- 2026-08-07 UPDATE: Structure Therapeutics (GPCR) - Phase 3 Is Dosing, and the Stock Already Knows 🔒 Paid
- 2026-05-08 UPDATE: Structure Therapeutics (GPCR) - The 16.3% Print and the Quiet ATM Upsize 🔒 Paid
- 2026-04-28 Structure Therapeutics (GPCR) - Scientific Deep Dive for Aleniglipron and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (5 calls)
Every verdict Biotech Distilled has published on Structure Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-04-28 Buy core Structure Therapeutics (GPCR) - Scientific Deep Dive for Aleniglipron and Pipeline Products Aleniglipron's best-in-class small-molecule oral GLP-1 platform with 15.3% placebo-adjusted weight loss, clean liver safety, $1.5B war chest, and exceptionally high M&A appeal make GPCR a high-conviction buyout candidate ahead of Phase 3 initiation.
- 2026-05-08 Buy core UPDATE: Structure Therapeutics (GPCR) - The 16.3% Print and the Quiet ATM Upsize Data improved to 16.3% placebo-adjusted weight loss and FDA gave clean end-of-Phase-2 guidance, but the ATM uncapping signals management is prepared to fund through Phase 3 independently, adding dilution risk to an otherwise stronger thesis.
- 2026-08-07 Buy core UPDATE: Structure Therapeutics (GPCR) - Phase 3 Is Dosing, and the Stock Already Knows Phase 3 ACCOMPLISH initiated on schedule with the best-performing dose, FDA alignment confirmed, Nature Medicine publication, and Novo obesity commercial chief hired — every milestone from the original thesis has been hit or is on schedule.
- 2026-09-09 Hold UPDATE: Structure Therapeutics (GPCR) - The Amylin Data Landed, and So Did the Stock Aleniglipron's 72-week durability and improved tolerability remain strong, but ACCG-2671's unresolved therapeutic window between tolerable and effective doses pushes the franchise-validating datapoint to 1H 2027, repricing the second leg of the thesis.
- 2026-11-10 Hold UPDATE: Structure Therapeutics (GPCR) - Half the Price, Same Molecule Despite a 47% drawdown since September, the drug's data is unchanged; however, accelerating burn, WuXi supply-chain geopolitical risk, CTO departure, and combination trial slip justify maintaining HOLD pending Q4 body composition and other readouts.
- Long call · opened Apr 28, 2026 at $43.56 · -58.3% vs XBI +10.8% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (4 quotes from 3 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“87% of eligible participants enrolled in the OLE ** All cohorts transitioned from either 90 mg or 120 mg to 180 mg after Week 60 Double Blind Treatment Period N=28 N=42 N=43 N=38 Weeks 0 36 44 56 72 ACCESS OLE Topline Results in September 2026 Reported in December 2025 180 mg 120 mg** Published: June 5, 2026 DOI: 10.1038/s41591 - 026 - 04476 - 6 60 120 mg** transition to 2.5 mg Cross over * 45 180 mg 90 180 mg 120 180 mg * Cross over from placebo in the ACCESS double - blind treatment period 180 mg 120 mg** transition to 180 mg 120 mg** transition to 180 mg 19 ACCESS OLE Baseline Demographics”
matched to aleniglipron · topline data
-
-
-
“We expect to report initial Phase 1 Single Ascending Dose (“SAD”) trial results for ACCG-2671 and advance it into Phase 2 Multiple Ascending Dose (“MAD”) trial in the third quarter of 2026.”
matched to ACCG-2671 · readout other -
“In August 2026, we initiated the Phase 3 ACCOMPLISH program, which includes two clinical trials evaluating aleniglipron.”
matched to aleniglipron · topline data / matched to aleniglipron · trial initiation
-
-
-
“We expect to report initial Phase 1 Single Ascending Dose (“SAD”) trial results for ACCG-2671 and advance it into Phase 2 Multiple Ascending Dose (“MAD”) trial in the third quarter of 2026.”
matched to ACCG-2671 · readout other
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (20)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 26, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 9, 2026ReleaseStructure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights→ BD updateSummary on the 8-K
- Nov 9, 20268-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1→ BD updateStructure Therapeutics' Q3 10-Q reveals a $134.6M R&D quarter — 128% above prior year — while burying a CTO departure effective November 13 that subscribers almost certainly missed. Three data catalysts are queued for Q4 2026 and the burn math is getting harder to ignore.
- Nov 9, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 4, 2026ReleaseStructure Therapeutics to Participate in the Jefferies Global Healthcare Conference
- Oct 19, 2026ReleaseStructure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026
- Sep 8, 2026ReleaseStructure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management→ BD updateSummary on the 8-K
- Sep 8, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1→ BD updateGPCR's most anticipated catalyst just landed — first human data for its oral amylin asset ACCG-2671 plus 72-week durability confirmation for aleniglipron — and the stock is down 23% from the August high. The data looks good. The market disagrees. Here's why.BD extracted 2 program updates from this document → GPCR pipeline
- Sep 3, 2026ReleaseStructure Therapeutics to Participate in Upcoming Healthcare Investor Conferences
- Aug 6, 2026ReleaseStructure Therapeutics Reports Second Quarter 2026 Financial Results and Recent HighlightsBD extracted 1 program update from this document → GPCR pipeline
- Aug 6, 20268-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- Aug 6, 202610-QQuarterly reportBD extracted 1 program update from this document → GPCR pipeline
- Jun 18, 20268-KCurrent report: shareholder vote
- Jun 5, 2026ReleaseStructure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for ObesityBD extracted 1 program update from this document → GPCR pipeline
- May 26, 2026ReleaseStructure Therapeutics Announces Participation in Upcoming Investor Conferences
- May 7, 20268-KCurrent report: material agreement, results of operations, other events · EX-99.1 EXHIBIT 99.1
- May 7, 2026424B5Prospectus supplement (offering)
- May 7, 202610-QQuarterly report
- Apr 23, 2026DEF 14AProxy statement
- Apr 15, 20268-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- Mar 16, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
5 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 5, 2026SCHEDULE 13G/A13G amendment
- Aug 6, 2026SCHEDULE 13G/A13G amendment
- Apr 23, 2026ARSAnnual report to shareholders